Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.
In this multicentric random double-blind study versus placebo, the therapeutic activity of timed-release dihydroergotamine preparation 10 mg/per os/day has been tested in 90 patients affected by common migraine. The drug presented a prophylactic effect on recurrent headache, mainly on night and awakening migraine. A low incidence of side-effects with no weight changes or other effects on physiologic events was registered.
D000328:Adult; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004087:Dihydroergotamine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy / Q000517:prevention & control*; D011897:Random Allocation; D012008:Recurrence
D003692:Delayed-Action Preparations; D004087:Dihydroergotamine